Product Information
GNP HEMORRHOIDAL PAIN RLF CRM is a generic product labeled by AmerisourceBergen, priced at $0.1313 per GM under NDC 46122077637. Its NADAC has been published 59 times since Aug 20, 2025.
Strength
144; 150; 25; 10 mg/g; mg/g; mg/g; mg/g
Manufacturer
AmerisourceBergenNDC
46122077637
Classification
Generic
Dosage Form
CREAM
Route
TOPICAL
Effective Date
9/23/2026
Approval Type
OTC MONOGRAPH DRUG
FDA Application
M015On Market Since
10/9/2024
Pharmacological Classes
Price Statistics
The NADAC for GNP HEMORRHOIDAL PAIN RLF CRM has been published 59 times since Aug 20, 2025, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1313 per GM |
|---|---|
| All-time high | $0.1328 (Jun 10, 2026) |
| All-time low | $0.1292 (Aug 20, 2025) |
| 52-week high | $0.1328 |
| 52-week low | $0.1296 |
| Median price | $0.1305 |
| Average price | $0.1307 |
| Largest weekly change | +1.1% (May 20, 2026) |
| Weeks tracked | 59 |
| Tracking since | Aug 20, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Hemorrhoidal market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
AmerisourceBergen manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Hemorrhoidal market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Non-Standardized Chemical Allergen class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GNP HEMORRHOIDAL PAIN RLF CRM?
The current National Average Drug Acquisition Cost (NADAC) for GNP HEMORRHOIDAL PAIN RLF CRM, manufactured by AmerisourceBergen, is $0.1313 per GM (NDC 46122077637), effective Sep 30, 2026.
How has the price of GNP HEMORRHOIDAL PAIN RLF CRM changed over time?
Over the history we have for it, the NADAC for GNP HEMORRHOIDAL PAIN RLF CRM has held within roughly two percent of its current level. It has been tracked across 59 weekly CMS publications since Aug 20, 2025.
What are the highest and lowest recorded NADAC prices for GNP HEMORRHOIDAL PAIN RLF CRM?
Since Aug 20, 2025, the NADAC for GNP HEMORRHOIDAL PAIN RLF CRM has ranged from a low of $0.1292 (Aug 20, 2025) to a high of $0.1328 (Jun 10, 2026), with a median of $0.1305 per GM.
Are there cheaper alternatives to GNP HEMORRHOIDAL PAIN RLF CRM?
No other NADAC-published product currently shares the active ingredient and strength of GNP HEMORRHOIDAL PAIN RLF CRM in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures GNP HEMORRHOIDAL PAIN RLF CRM?
GNP HEMORRHOIDAL PAIN RLF CRM (NDC 46122077637) is labeled by AmerisourceBergen, and CMS classifies it as a generic product.